We conducted a double-blind, placebo-controlled trial of the efficacy of oral azidothymidine (AZT) in 282 patients with the acquired immunodeficiency syndrome (AIDS) manifested by Pneumocystis carinii pneumonia alone, or with advanced AIDS-related complex. The subjects were stratified according to numbers of T cells with CD4 surface markers and were randomly assigned to receive either 250 mg of AZT or placebo by mouth every four hours for a total of 24 weeks. One hundred forty-five subjects received AZT, and 137 received placebo. When the study was terminated, 27 subjects had completed 24 weeks of the study, 152 had completed 16 weeks, and the remainder had completed at least 8 weeks. Nineteen placebo recipients and 1 AZT recipient died during the study (P less than 0.001). Opportunistic infections developed in 45 subjects receiving placebo, as compared with 24 receiving AZT. The base-line Karnofsky performance score and weight increased significantly among AZT recipients (P less than 0.001). A statistically significant increase in the number of CD4 cells was noted in subjects receiving AZT (P less than 0.001). After 12 weeks, the number of CD4 cells declined to pretreatment values among AZT recipients with AIDS but not amonG AZT recipients with AIDS-related complex. Skin-test anergy was partially reversed in 29 percent of subjects receiving AZT, as compared with 9 percent of those receiving placebo (P less than 0.001). These data demonstrate that AZT administration can decrease mortality and the frequency of opportunistic infections in a selected group of subjects with AIDS or AIDS-related complex, at least over the 8 to 24 weeks of observation in this study.
This article has been cited by other articles:
Jimenez-Nacher, I., Garcia, B., Barreiro, P., Rodriguez-Novoa, S., Morello, J., Gonzalez-Lahoz, J., de Mendoza, C., Soriano, V.
(2008). Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother
62: 816-822
[Abstract][Full Text]
McCown, M. F., Rajyaguru, S., Le Pogam, S., Ali, S., Jiang, W.-R., Kang, H., Symons, J., Cammack, N., Najera, I.
(2008). The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors. Antimicrob. Agents Chemother.
52: 1604-1612
[Abstract][Full Text]
Buckheit, R. W. Jr., Hartman, T. L., Watson, K. M., Chung, S.-G., Cho, E.-H.
(2008). Comparative Evaluation of the Inhibitory Activities of a Series of Pyrimidinedione Congeners That Inhibit Human Immunodeficiency Virus Types 1 and 2. Antimicrob. Agents Chemother.
52: 225-236
[Abstract][Full Text]
Allard, R., Boivin, J.-F.
(2007). Using causal models to show the effect of untestable assumptions on effect estimates in randomized controlled trials. Clin Trials
4: 611-620
[Abstract]
Roth-Cline, M. D.
(2006). Clinical Trials in the Wake of Vioxx: Requiring Statistically Extreme Evidence of Benefit to Ensure the Safety of New Drugs. Circulation
113: 2253-2259
[Full Text]
Mocroft, A, Neaton, J, Bebchuk, J, Staszewski, S, Antunes, F, Knysz, B, Law, M, Phillips, A N, Lundgren, J D
(2006). The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clin Trials
3: 119-132
[Abstract]
Orkin, C., Stebbing, J., Nelson, M., Bower, M., Johnson, M., Mandalia, S., Jones, R., Moyle, G., Fisher, M., Gazzard, B.
(2005). A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother
55: 246-251
[Abstract][Full Text]
Shepherd, J. P.
(2003). Explaining Feast or Famine in Randomized Field Trials: Medical Science and Criminology Compared. Eval Rev
27: 290-315
[Abstract]
Isaac, A, Pillay, D
(2003). New drugs for treating drug resistant HIV-1. Sex. Transm. Infect.
79: 176-178
[Full Text]
Monini, P., Sgadari, C., Barillari, G., Ensoli, B.
(2003). HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity. J Antimicrob Chemother
51: 207-211
[Full Text]
Sturmer, M., Staszewski, S., Doerr, H.-W., Larder, B., Bloor, S., Hertogs, K.
(2003). Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214. Antimicrob. Agents Chemother.
47: 54-61
[Abstract][Full Text]
Taggart, S., Breen, R., Goldsack, N., Sabin, C., Johnson, M., Lipman, M.
(2002). The Changing Pattern of Bronchoscopy in an HIV-Infected Population*. Chest
122: 878-885
[Abstract][Full Text]
Jordan, R., Gold, L., Cummins, C., Hyde, C.
(2002). Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ
324: 757-757
[Abstract][Full Text]
Iglesias-Ussel, M. D., Casado, C., Yuste, E., Olivares, I., Lopez-Galindez, C.
(2002). In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J. Gen. Virol.
83: 93-101
[Abstract][Full Text]
Reefschlaeger, J., Bender, W., Hallenberger, S., Weber, O., Eckenberg, P., Goldmann, S., Haerter, M., Buerger, I., Trappe, J., Herrington, J. A., Haebich, D., Ruebsamen-Waigmann, H.
(2001). Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother
48: 757-767
[Abstract][Full Text]
Sepkowitz, K. A.
(2001). AIDS -- The First 20 Years. NEJM
344: 1764-1772
[Full Text]
Sabin, C. A., Phillips, A. N.
(2001). Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. J Antimicrob Chemother
47: 371-375
[Full Text]
(2001). Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch. Dis. Child.
84: 230-236
[Abstract][Full Text]
Hong, M., Schlichter, L., Bendayan, R.
(2001). A Novel Zidovudine Uptake System in Microglia. J. Pharmacol. Exp. Ther.
296: 141-149
[Abstract][Full Text]
Brocavich, J. M., Etzel, J. V., Kanmaz, T. J.
(2000). Introduction: Therapeutic Issues in the Management of Patients Infected with the Human Immunodeficiency Virus (HIV). Journal of Pharmacy Practice
13: 422-425
DOHN, M. N., WHITE, M. L., VIGDORTH, E. M., RALPH BUNCHER, C., HERTZBERG, V. S., BAUGHMAN, R. P., GEORGE SMULIAN, A., WALZER, P. D.
(2000). Geographic Clustering of Pneumocystis carinii Pneumonia in Patients with HIV Infection. Am. J. Respir. Crit. Care Med.
162: 1617-1621
[Abstract][Full Text]
Halvas, E. K., Svarovskaia, E. S., Freed, E. O., Pathak, V. K.
(2000). Wild-Type and YMDD Mutant Murine Leukemia Virus Reverse Transcriptases Are Resistant to 2',3'-Dideoxy-3'-Thiacytidine. J. Virol.
74: 6669-6674
[Abstract][Full Text]
Barbier, O., Turgeon, D., Girard, C., Green, M. D., Tephly, T. R., Hum, D. W., Bélanger, A.
(2000). 3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos.
28: 497-502
[Abstract][Full Text]
Meng, Q., Su, T., Olivero, O. A., Poirier, M. C., Shi, X., Ding, X., Walker, V. E.
(2000). Relationships between DNA Incorporation, Mutant Frequency, and Loss of Heterozygosity at the TK Locus in Human Lymphoblastoid Cells Exposed to 3'-Azido-3'-deoxythymidine. Toxicol Sci
54: 322-329
[Abstract][Full Text]
Oyesanmi, O., Kunkel, E. J.S., Monti, D. A., Field, H. L.
(1999). Hematologic Side Effects of Psychotropics. Psychosomatics
40: 414-421
[Abstract][Full Text]
Engelson, E. S, Kotler, D. P, Tan, Y., Agin, D., Wang, J., Pierson, R. N Jr, Heymsfield, S. B
(1999). Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am. J. Clin. Nutr.
69: 1162-1169
[Abstract][Full Text]
Makadon, H. J.
(1999). An Asymptomatic 41-Year-Old Man With HIV Infection. JAMA
281: 739-744
[Full Text]
Zhou, X.-J., Sheiner, L. B., D'Aquila, R. T., Hughes, M. D., Hirsch, M. S., Fischl, M. A., Johnson, V. A., Myers, M., Sommadossi, J.-P., The National Institute of Allergy and Infectious D,
(1999). Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother.
43: 121-128
[Abstract][Full Text]
(1998). Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. Pediatrics
102: 1005-1062
[Full Text]
ASH, S.
(1998). Combination HIV therapy and opportunistic infections of the eye in people with AIDS. Br J Ophthalmol
82: 981-982
[Full Text]
Powderly, W. G., Landay, A., Lederman, M. M.
(1998). Recovery of the Immune System With Antiretroviral Therapy: The End of Opportunism?. JAMA
280: 72-77
[Abstract][Full Text]
Arts, E. J., Quinones-Mateu, M. E., Albright, J. L., Marois, J.-P., Hough, C., Gu, Z., Wainberg, M. A.
(1998). 3'-Azido-3'-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants. J. Virol.
72: 4858-4865
[Abstract][Full Text]
Kemp, S. D., Shi, C., Bloor, S., Harrigan, P. R., Mellors, J. W., Larder, B. A.
(1998). A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and L-2',3'-Dideoxy-3'-Thiacytidine. J. Virol.
72: 5093-5098
[Abstract][Full Text]
Paltiel, A. D., Freedberg, K. A.
(1998). The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients. Interfaces
28: 34-51
[Abstract]
Paltiel, A. D., Scharfstein, J. A., Seage, G. R., Losina, E., Goldie, S. J., Weinstein, M. C., Craven, D. E., Freedberg, K. A.
(1998). A Monte Carlo Simulation of Advanced HIV Disease: Application to Prevention of CMV Infection. Med Decis Making
18: S93-S105
[Abstract]
Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J. P., O'Shaughnessy, M. V., Schechter, M. T., Montaner, J. S. G.
(1998). Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral Therapy. JAMA
279: 450-454
[Abstract][Full Text]
Difalco, M. R., Dufresne, L., Congote, L. F.
(1998). Efficacy of an Insulin-Like Growth Factor-Interleukin-3 Fusion Protein in Reversing the Hematopoietic Toxicity Associated with Azidothymidine in Mice. J. Pharmacol. Exp. Ther.
284: 449-454
[Abstract][Full Text]
Smith, G. D., Egger, M., Phillips, A. N
(1997). Meta-analysis: Beyond the grand mean?. BMJ
315: 1610-1614
[Full Text]
Chang, M., Sood, V. K., Kloosterman, D. A., Hauer, M. J., Fagerness, P. E., Sanders, P. E., Vrbanac, J. J.
(1997). Identification of the Metabolites of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine in Monkeys. Drug Metab. Dispos.
25: 814-827
[Abstract][Full Text]
Chang, M., Sood, V. K., Wilson, G. J., Kloosterman, D. A., Sanders, P. E., Hauer, M. J., Zhang, W., Branstetter, D. G.
(1997). Metabolism of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine In Mice. Drug Metab. Dispos.
25: 828-839
[Abstract][Full Text]
Chang, M., Sood, V. K., Wilson, G. J., Kloosterman, D. A., Sanders, P. E., Hauer, M. J., Fagerness, P. E.
(1997). Metabolism of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Delavirdine in Rats. Drug Metab. Dispos.
25: 228-242
[Abstract][Full Text]
Tosi, P., Gherlinzoni, F., Mazza, P., Visani, G., Coronado, O., Costigliola, P., Raise, E., Mazzetti, M., Gritti, F., Chiodo, F., Tura, S.
(1997). 3'-Azido 3'-Deoxythymidine + Methotrexate as a Novel Antineoplastic Combination in the Treatment of Human Immunodeficiency Virus-Related Non-Hodgkin's Lymphomas. Blood
89: 419-425
[Abstract][Full Text]
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., Hirsch, M. S., Merigan, T. C., The AIDS Clinical Trials Group Study 175 Study Tea,
(1996). A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter. NEJM
335: 1081-1090
[Abstract][Full Text]
Phillips, A. N, Smith, G. D., Johnson, M. A
(1996). For Debate: Will we ever know when to treat HIV infection?. BMJ
313: 608-610
[Full Text]
Staszewski, S., Loveday, C., Picazo, J. J., Dellamonica, P., Skinhoj, P., Johnson, M. A., Danner, S. A., Harrigan, P. R., Hill, A. M., Verity, L., McDade, H.
(1996). Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy. JAMA
276: 111-117
[Abstract]
Katlama, C., Ingrand, D., Loveday, C., Clumeck, N., Mallolas, J., Staszewski, S., Johnson, M., Hill, A. M., Pearce, G., McDade, H.
(1996). Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Antiretroviral-Naive Patients: A Randomized Controlled Comparison With Zidovudine Monotherapy. JAMA
276: 118-125
[Abstract]
Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schooley, R. T., Thompson, M. A., Vella, S., Yeni, P. G., Volberding, P. A.
(1996). Antiretroviral Therapy for HIV Infection in 1996: Recommendations of an International Panel. JAMA
276: 146-154
[Abstract]
Moore, R. D., Keruly, J. C., Chaisson, R. E.
(1996). Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection. Arch Intern Med
156: 1073-1077
[Abstract]
Enger, C., Graham, N., Peng, Y., Chmiel, J. S., Kingsley, L. A., Detels, R., Munoz, A.
(1996). Survival From Early, Intermediate, and Late Stages of HIV Infection. JAMA
275: 1329-1334
[Abstract]
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., Corey, L., The AIDS Clinical Trials Group,
(1996). Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine. NEJM
334: 1011-1018
[Abstract][Full Text]
Stewart, G. M., Gregory, B. C.
(1996). Themes of a Long-Term AIDS Support Group for Gay Men. The Counseling Psychologist
24: 285-303
[Abstract]
Karp, C. L., Scott, I. U., Chang, T. S., Pflugfelder, S. C.
(1996). Conjunctival Intraepithelial Neoplasia: A Possible Marker for Human Immunodeficiency Virus Infection?. Arch Ophthalmol
114: 257-261
[Abstract]
Laraque, F., Greene, A., Triano-Davis, J. W., Altman, R., Lin-Greenberg, A.
(1996). Effect of Comprehensive Intervention Program on Survival of Patients With Human Immunodeficiency Virus Infection. Arch Intern Med
156: 169-176
[Abstract]
Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., Rubin, M., The North American HIV Working Party,
(1995). Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter. NEJM
333: 1662-1669
[Abstract][Full Text]
Czachor, J. S., Gleckman, R. A.
(1995). Selective Causes of Fever in Adult Human Immunodeficiency Virus--Infected Patients Relative to CD4+ Cell Counts. Arch Fam Med
4: 879-884
[Abstract]
Chaisson, R. E., Keruly, J. C., Moore, R. D.
(1995). Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus Disease. NEJM
333: 751-756
[Abstract][Full Text]
Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Rooney, J., Meng, T.-C., Fischl, M. A., Collier, A. C., Phair, J. P., Hirsch, M. S., Hardy, W. D., Balfour, H. H., Reichman, R. C., The AIDS Clinical Trials Group,
(1995). A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter. NEJM
333: 401-407
[Abstract][Full Text]
Kinloch-de Loes, S., Hirschel, B. J., Hoen, B., Cooper, D. A., Tindall, B., Carr, A., Saurat, J.-H., Clumeck, N., Lazzarin, A., Mathiesen, L., Raffi, F., Antunes, F., von Overbeck, J., Luthy, R., Glauser, M., Hawkins, D., Baumberger, C., Yerly, S., Perneger, T. V., Perrin, L.
(1995). A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection. NEJM
333: 408-413
[Abstract][Full Text]
Eriksson, S., Xu, B., Clayton, D. A.
(1995). Efficient Incorporation of Anti-HIV Deoxynucleotides by Recombinant Yeast Mitochondrial DNA Polymerase. J. Biol. Chem.
270: 18929-18934
[Abstract][Full Text]
Antonucci, G., Girardi, E., Raviglione, M. C., Ippolito, G., for the Gruppo Italiano di Studio Tubercolosi e AI, , Almi, P., Angarano, G., Armignacco, O., Babudieri, S., Bevilacqua, N., Bini, A., Bottura, P., Boumis, E., Costigliola, P., Chirianni, A., Di Perri, G., Errante, I., Libanore, M., Manzillo, E., Minoli, L., Narciso, P., Pagano, G., Pellizzer, G., Rapiti, E., Rusconi, S., Santoro, D., Savalli, E., Tavio, M., Traverso, A., Viale, P.
(1995). Risk Factors for Tuberculosis in HIV-lnfected Persons: A Prospective Cohort Study. JAMA
274: 143-148
[Abstract]
Mao, F., Rechtin, T. M., Jones, R., Cantu, A. A., Anderson, L. S., Radominska, A., Moyer, M. P., Drake, R. R.
(1995). Synthesis of a Photoaffinity Analog of 3`-Azidothymidine, 5-Azido-3`-azido-2`,3`-dideoxyuridine. J. Biol. Chem.
270: 13660-13664
[Abstract][Full Text]
Dolin, R., Amato, D. A., Fischl, M. A., Pettinelli, C., Beltangady, M., Liou, S.-h., Brown, M. J., Cross, A. P., Hirsch, M. S., Hardy, W. D., Mildvan, D., Blair, D. C., Powderly, W. G., Para, M. F., Fife, K. H., Steigbigel, R. T., Smaldone, L., AIDS Clinical Trials Group, , National Institute of Allergy and Infectious Disea, , National Institutes of Health, , Bristol-Myers Squibb, , Crumpacker, C. S., Cooley, T., Mitsuyaso, R. T., John, R., Sanders, C., Reitman, D., Hewitt, R., Reichman, R. C., Gelb, L. D., McGuire, M. L., Jones, M., Neidig, J. L., Zwickl, B., Hartman, P. B., Roarke, M. E., Burk, R. A., Fuhrer, J., Somogyi, K. A., Sepkowitz, K., Telzak, E. E., McAuliffe, V. J., Valentine, F. T., Vasquez, M., Merigan, T. C., Katzenstein, D., Fessell, J., Havlir, D. V., Richman, D. D., Spector, S. A., Kahn, J. O., Johnson, L., Coleman, R., Ho, M., McMahon, D., Pazin, G., Antoniskis, D., McNamara, B., Diamond, D., Collier, A. C., Paradise, M. A., Wald, A., DePaolis-Jones, A., Henry, K., Waskin, H. A., Hyslop, N. E. Jr, Mushatt, D. M., Zachary, J. A., Soeiro, R., Harris, C., Zingman, B., Giordano, M. F., Sledz, S., Murray, H. W., Carey, J. T., Davis, T. L., Bagby, B., Kessler, H. A., Murphy, R. I., Hirschtick, R. E., Cheeseman, S. H., Lai, K. K., Fairchild, P. G., Ehmann, W. C., Zurlo, J. J., Millard, R., Troiani, L., Heggen, A. A., van der Horst, C. M., McKinley, G. F., Grieco, M. H., Kolatch, B. R., Goldsmith, J. C., Gomperts, E. D., Woods, L. M., Grue, L., Mayjo, K., Becker, R. L., Jayaweera, D. T., Rolfe, L., Cole, J., Jermano, J.
(1995). Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine. Arch Intern Med
155: 961-974
[Abstract]
Lundgren, J. D., Barton, S. E., Katlama, C., Ledergerber, B., Gonzalez-Lahoz, J., Pinching, A. J., Proenca, R., Hemmer, R., Pedersen, C., Phillips, A. N., Multicentre Study Group on AIDS in Europe, , DeWit, S., Sommereijns, B., Lundgren, J., Nielsen, T., Pedersen, C., Jensen, G., Skinhoj, P., Bentsen, K., Gerstoft, J., Melbye, M., Valle, S.-L., Berlureau, P., Schwander, S., Goebel, F.-D., Stergiou, G., Gouzia, T., Papadopoulos, A., Ben-lshai, Z., Bentwich, Z., Sacks, T., Maayan, S., Calonghi, G., Nuova, A. S. M., Emilia, R., Cargnel, A., Sacco, O., Arlotti, M., Ciammarughi, R., Colomba, A., DeLalla, F., Fassio, P., Ferlini, A., Fiaccadori, F., Pasetti, G., Giannelli, F., Grillone, W., Lazzarin, A., Monforte, A. D., Sacco, O. L., Mignani, E., Andrea, O. S., Nunnari, A., Ortona, L., Panichi, G., Pauluzzi, S., Piersantelli, N., Ranieri, S., Ricciardiello, P., Roscioli, B., Soranzo, M., Bloemkolk, D., Proenca, R., Martinez-Blanco, L., Clotet, B., Gatell, J., Buira, E., Ledergerber, B., Olsson, C., Glauser, M., Hirschel, B., Hawkes, S., Phillips, A., Barton, S., Morcinek, J., Pinching, A., Coleman, D., Gjorup, I., Lundgren, J., Nielsen, J., Nieport, C., Pedersen, C., Teglbjaerg, L., Thornval, A.
(1995). Changes in Survival Over Time After a First Episode of Pneumocystis carinii Pneumonia for European Patients With Acquired Immunodeficiency Syndrome. Arch Intern Med
155: 822-828
[Abstract]
Kovacs, J. A., Baseler, M., Dewar, R. J., Vogel, S., Davey, R. T., Falloon, J., Polis, M. A., Walker, R. E., Stevens, R., Salzman, N. P., Metcalf, J. A., Masur, H., Lane, H. C.
(1995). Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection -- A Preliminary Study. NEJM
332: 567-575
[Abstract][Full Text]
Barry, H. C., Justice, A. C., Hack, T. C., Markson, L. E., Turner, B. J., Ayanian, J. Z.
(1995). Knowledge of Drugs for Myocardial Infarction: Generalists versus Specialists. NEJM
332: 472-474
[Full Text]
Markson, L. E., Cosler, L. E., Turner, B. J.
(1995). Generalists' Prudence May Lead to Better Outcomes-Reply. Arch Intern Med
155: 336-337
[Abstract]
Coffin, J.
(1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science
267: 483-489
[Abstract]
Bozzette, S. A., Kanouse, D. E., Berry, S., Duan, N., R, , Gocke, D. J., Marlowe, S. I., Pottage, J. C. Jr, Follansbee, S. E., Remick, S., Klimas, N., Jensen, P., Henry, D. H., Olson, R., Turner, P. A., Lalezari, J. P., Phair, J., Pollard, R., Pierce, P. F., Saravolatz, L. D., Cohen, S., Cate, T., Pegram, P. S., Spotkov, J., Carey, J. T., Perez, G., Pettinelli, C., DownesLeGuin, T., Hill, D., Edwards, C., Mazel, R., Hays, R., Stewart, A., Soo, W., Salgo, M., Anthony, M., Dixon, D., Myers, M.
(1995). Health Status and Function With Zidovudine or Zalcitabine as Initial Therapy for AIDS: A Randomized Controlled Trial. JAMA
273: 295-301
[Abstract]
Forseter, G., Joline, C., Wormser, G. P.
(1994). Tolerability, Safety, and Acceptability of Zidovudine Prophylaxis in Health Care Workers. Arch Intern Med
154: 2745-2749
[Abstract]
Musicco, M., Lazzarin, A., Nicolosi, A., Gasparini, M., Costigliola, P., Arici, C., Saracco, A., Italian Study Group on HIV Heterosexual Transmissi,
(1994). Antiretroviral Treatment of Men Infected With Human Immunodeficiency Virus Type 1 Reduces the Incidence of Heterosexual Transmission. Arch Intern Med
154: 1971-1976
[Abstract]
Volberding, P. A., Lagakos, S. W., Grimes, J. M., Stein, D. S., Balfour, H. H. Jr, Reichman, R. C., Bartlett, J. A., Hirsch, M. S., Phair, J. P., Mitsuyasu, R. T., Fischl, M. A., Soeiro, R., the AIDS Clinical Trials Group of the National Ins, , Pettinelli, C. B., Martinez, A. I., Liou, S.-H., Henry, K., Simpson, M., DePaolis-Jones, A., Hewitt, R. G., Blair, D. C., Packard, M. V., Fowler, C., Crumpacker, C. S., Allan, J. D., Fitch, H. F., Dybeck, K., Coleman, R., Jacobson, M., Phair, J. P., Murphy, R., Benson, C., Hardy, W. D., Chafey, S. A., Kruger, S., Reese, J., Dale, E., Harris, C., Steigbigel, N., Becker, R. L., Rexroad, V. E., Feinberg, J. E., Spector, S. A., Richman, D. D., Snyder, R., Merigan, T. C. Jr, Fessel, J., Katzenstein, D., Zachary, J. A., Mushatt, D. M., Hyslop, N. E. Jr, Collier, A. C., Corey, L., Coombs, R. W., Para, M. F., Fass, R. J., Whitacre, C., Sacks, H. S., Mildvan, D., Mendoza, H., Fife, K., Powderly, W. G., Gelb, L. D., Klebert, M., Leedom, J. M., Liggins, M., Quesada, N., Wong, B., Brinkdopke, J., Hoelle, M., Gocke, D. J., McAuliffe, V. J., Valentine, F. T., Dowling, J., Wallace, M., PaulJarrett, V., Cargill, V., McKinley, G. F., Grieco, M. H., Polsky, B., Brown, D. C., van der Horst, C., Fiscus, S., Ragan, D., Cheeseman, S. H., Fairchild, P. G., Lai, K. K., Ho, M., McMahon, D., Armstrong, J. A., Eyster, M. E., Ehmann, W. C., Irwin, D., Steigbigel, R. T., Fuhrer, J., Tenzler, R., Ponticello, L., Giordano, M. F., Murray, H. W.
(1994). The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection: Prolonged Evaluation of Protocol 019 of the AIDS Clinical Trials Group. JAMA
272: 437-442
[Abstract]
Turner, B. J., Hecht, F. M., Ismail, R. B.
(1994). CD4+ T-Lymphocyte Measures in the Treatment of Individuals Infected With Human Immunodeficiency Virus Type 1: A Review for Clinical Practitioners. Arch Intern Med
154: 1561-1573
[Abstract]
Markson, L. E., Cosler, L. E., Turner, B. J.
(1994). Implications of Generalists' Slow Adoption of Zidovudine in Clinical Practice. Arch Intern Med
154: 1497-1504
[Abstract]
Lundgren, J D, Pedersen, C, Clumeck, N, Gatell, J M, Johnson, A M, Ledergerber, B, Vella, S, Phillips, A, Nielsen, J O
(1994). Survival differences in European patients with AIDS, 1979-89. BMJ
308: 1068-7103
[Abstract][Full Text]
Osmond, D., Charlebois, E., Lang, W., Shiboski, S., Moss, A.
(1994). Changes in AIDS Survival Time in Two San Francisco Cohorts of Homosexual Men, 1983 to 1993. JAMA
271: 1083-1087
[Abstract]
Lundgren, J. D., Phillips, A. N., Pedersen, C., Clumeck, N., Gatell, J. M., Johnson, A. M., Ledergerber, B., Vella, S., Nielsen, J. O., Clumeck, N., DeWit, S., Sommereijns, B., Nielsen, J. O., Lundgren, J., Nielsen, T., Pedersen, C., Jensen, G., Skinhoj, P., Bentsen, K., Gerstoft, J., Melbye, M., Ranki, A., Valle, S.-L., Katlama, C., Berlureau, P., Dietrich, M., Schwander, S., Goebel, F.-D., Kosmidis, J., Stergiou, G., Gouzia, T., Papadopoulos, A., Banhegyi, D., Mulcahy, F., Yust, I., Ben-Ishai, Z., Bentwich, Z., Sacks, T., Maayan, S., Vella, S., Chiesi, A., Ancarani, F., Scalise, G., Bertaggia, A., Francavilla, E., Calonghi, G., Nuova, A. S. M., Emilia, R., Cargnel, A., Arlotti, M., Ciammarughi, R., Colomba, A., DeLalla, F., Fassio, P., Ferlini, A., Fiaccadori, F., Pasetti, G., Giannelli, F., Grillone, W., Lazzarin, A, Monforte, A. D., Mignani, E., Nunnari, A., Ortona, L., Panichi, G., Pauluzzi, S., Piersantelli, N., Ranieri, S., Ricciardiello, P., Roscioli, B., Soranzo, M., Hemmer, R., Danner, S., Bloemkolk, D., Antunes, F., Proenca, R., Gonzalez-Lahoz, J., Martinez-Blanco, L., Clotet, B., Gatell, J., Buira, E., Miro, J., Pehrson, P., Luthy, R., Ledergerber, B., Olsson, K., Glauser, M., Hirschel, B., Johnson, A., Hawkes, S., Phillips, A., Barton, S., Morcinek, J., Pinching, A., Coleman, D., Gjprup, I., Lundgren, J., Nielsen, J., Nieport, C., Pedersen, C., Teglbjaerg, L., Thornval, A.
(1994). Comparison of Long-term Prognosis of Patients With AIDS Treated and Not Treated With Zidovudine. JAMA
271: 1088-1092
[Abstract]
Duvic, M., Crane, M. M., Conant, M., Mahoney, S. E., Reveille, J. D., Lehrman, S. N.
(1994). Zidovudine Improves Psoriasis in Human Immunodeficiency Virus--Positive Males. Arch Dermatol
130: 447-451
[Abstract]
Moore, R. D., Stanton, D., Gopalan, R., Chaisson, R. E.
(1994). Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community. NEJM
330: 763-768
[Abstract][Full Text]
Saag, M. S.
(1994). What to Do When Zidovudine Fails. NEJM
330: 706-707
[Full Text]
Smith, G D, Egger, M
(1994). Who benefits from medical interventions?. BMJ
308: 72-4
[Full Text]
Phair, J. P., Abels, R. I., McNeill, M. V., Sullivan, D. J.
(1993). Recombinant Human Erythropoietin Treatment: Investigational New Drug Protocol for the Anemia of the Acquired Immunodeficiency Syndrome: Overall Results. Arch Intern Med
153: 2669-2675
[Abstract]
Sande, M. A., Carpenter, C. C. J., Cobbs, C. G., Holmes, K. K., Sanford, J. P., the National Institute of Allergy and Infectious D, , Sande, M. A., Carpenter, C. C. J., Cobbs, C. G., Coombs, R. W., Fleming, T. R., Holmes, K. K., Denison, R., Gail, M. H., Greaves, W. L., Hirsch, M. S., Luskin-Hawk, R., Mildvan, D., Nelson, C. A., Phair, J. P., Sanford, J. P., Schooley, R., Torres, R. G., Vazquez, R., Deyton, L., Jermano, J., Koziol, J., Pettinelli, C., Katz, D.
(1993). Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference. JAMA
270: 2583-2589
[Abstract]
Saag, M. S., Emini, E. A., Laskin, O. L., Douglas, J., Lapidus, W. I., Schleif, W. A., Whitley, R. J., Hildebrand, C., Byrnes, V. W., Kappes, J. C., Anderson, K. W., Massari, F. E., Shaw, G. M., The 661 Working Group L-697,
(1993). A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. NEJM
329: 1065-1072
[Abstract][Full Text]
Cooper, D. A., Gatell, J. M., Kroon, S., Clumeck, N., Millard, J., Goebel, F.-D, Bruun, J. N., Stingl, G., Melville, R. L., Gonzalez-Lahoz, J., Stevens, J. W., Fiddian, A. P., The European-Australian Collaborative Group,
(1993). Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter. NEJM
329: 297-303
[Abstract][Full Text]
Bartlett, J. G.
(1993). Zidovudine Now or Later?. NEJM
329: 351-352
[Full Text]
Johnston, M., Hoth, D.
(1993). Present status and future prospects for HIV therapies. Science
260: 1286-1293
[Abstract]
Klein, R. S., Manian, F. A., LaRocco, A., Sanders, J. W., Myers, J. W., Bretagne, S., Gray, F., Costa, J.-M., Porter, S. B., Sande, M. A.
(1993). Central Nervous System Toxoplasmosis in AIDS. NEJM
328: 1352-1354
[Full Text]
Khaliq, Y., Lamp, K. C.
(1993). Comparing Pneumocystis carinii Pneumonia Prophylactic Regimens. Arch Intern Med
153: 782-783
[Abstract]
Jewett, J. F., Hecht, F. M.
(1993). Preventive Health Care for Adults With HIV Infection. JAMA
269: 1144-1153
[Abstract]
De Angelis, D., Day, N., Gore, S., Gilks, W., McGee, M.
(1993). AIDS: the statistical basis for public health. Stat Methods Med Res
2: 75-91
[Abstract]
Rietmeijer, C. A., Davidson, A. J., Foster, C. T., Cohn, D. L.
(1993). Cost of Care for Patients With Human Immunodeficiency Virus Infection: Patterns of Utilization and Charges in a Public Health Care System. Arch Intern Med
153: 219-225
[Abstract]
Sleasman, J. W., Hemenway, C., Klein, A. S., Barrett, D. J.
(1993). Corticosteroids Improve Survival of Children With AIDS and Pneumocystis carinii Pneumonia. Arch Pediatr Adolesc Med
147: 30-34
[Abstract]
Levenson, R. L. Jr, Ann Mellins, C., Zawadzki, R., Kairam, R., Stein, Z.
(1992). Cognitive Assessment of Human Immunodeficiency Virus-Exposed Children. Arch Pediatr Adolesc Med
146: 1479-1483
[Abstract]
Brandeau, M. L., Owens, D. K., Sox, C. H., Wachter, R. M.
(1992). Screening Women of Childbearing Age for Human Immunodeficiency Virus: A Cost-benefit Analysis. Arch Intern Med
152: 2229-2237
[Abstract]
Chaisson, R. E., Keruly, J., Richman, D. D., Moore, R. D.
(1992). Pneumocystis Prophylaxis and Survival in Patients With Advanced Human Immunodeficiency Virus Infection Treated With Zidovudine. Arch Intern Med
152: 2009-2013
[Abstract]
McLeod, G. X., Hammer, S. M.
(1992). Zidovudine: Five Years Later. ANN INTERN MED
117: 487-501
[Abstract]
Mofenson, L. M., Moye, J. Jr, Bethel, J., Hirschhorn, R., Jordan, C., Nugent, R., the National Institute of Child Health and Human D, , Willoughby, A., Mofenson, L. M., Nugent, R., Moye, J. Jr, Berendes, H. W., Rigau-Perez, J. G., Durako, S., Jordan, C., Rust, K., Hirschhorn, R., Bethel, J., Shah, K., Chow, J., Edelson, P., Sanders, D., Bonagura, V., Valacer, D., Henley, W., Bamji, M., Gupta, A., Li, K. I., Abrams, E. J., Fikrig, S., Bakshi, S. S., Pahwa, S., Krasinski, K., Pitt, J., Bernstein, L., Rubinstein, A., Johnson, G., Cooper, E. R., Frenkel, L., Lischner, H. W., Raphael, S. A., Johnson, J. P., Rakusan, T., Nesheim, S., Nahmias, A., Keyserling, H., Yogev, R., Chadwick, E., Rich, K., Shearer, W. T., Guerra-Hanson, I. C., Petru, A., Diaz, C., Santini, J. L. C., Jimenez, E., Garcia-Trias, D., Acantilado, C., Schwartz, R.
(1992). Prophylactic Intravenous Immunoglobulin in HIV-Infected Children With CD4+ Counts of 0.20x109/L or More: Effect on Viral, Opportunistic, and Bacterial Infections. JAMA
268: 483-488
[Abstract]
(1992). Diagnostic and Therapeutic Technology Assessment (DATTA). JAMA
267: 2948-2952
